Brief: Petros Pharmaceuticals Launches Two Self-Selection Studies For Erectile Dysfunction Drug Stendra® (Avanafil)
18/01/2022 14:35
Jan 18 (Reuters) - Petros Pharmaceuticals Inc PTPI.O :
* PETROS PHARMACEUTICALS LAUNCHES TWO SELF-SELECTION STUDIES
FOR
ERECTILE DYSFUNCTION DRUG STENDRA® (AVANAFIL)
* PETROS PHARMACEUTICALS INC - STUDIES ARE KEY NEXT STEP
TOWARD
FDA DISCUSSIONS ON POTENTIAL OTC LABELLING STATUS
Source text for Eikon: ID:nPn2zg4wPa
Further company coverage: PTPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Petros Pharmaceuticals
See all newsBrief: Petros Pharmaceuticals Assigns All Assets To Pt Liquidation, For Benefit Of Creditors
Brief: Petros Pharmaceuticals’ STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Brief: Petros Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Petros Pharmaceuticals Expands Online Distribution For Prescription STENDRA(R) Through New Agreement With Lemonaid Health
Brief: Petros Pharma Announces Partnership with Idea Evolver for Rx-to-OTC Switches & Digital Launch Solutions